Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Bronchoalveolar Lavage | 3 | 2021 | 603 | 1.50 | Why? |
| Bronchoscopy | 3 | 2020 | 991 | 0.93 | Why? |
| Electromagnetic Phenomena | 1 | 2018 | 21 | 0.77 | Why? |
| Hemoptysis | 2 | 2018 | 172 | 0.74 | Why? |
| Anti-Asthmatic Agents | 2 | 2020 | 427 | 0.73 | Why? |
| Solitary Pulmonary Nodule | 1 | 2018 | 83 | 0.68 | Why? |
| alpha 1-Antitrypsin Deficiency | 1 | 2018 | 94 | 0.65 | Why? |
| Asthma | 6 | 2020 | 4383 | 0.63 | Why? |
| Biological Therapy | 1 | 2020 | 456 | 0.60 | Why? |
| alpha 1-Antitrypsin | 1 | 2018 | 264 | 0.57 | Why? |
| Mycoses | 1 | 2021 | 589 | 0.56 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 2309 | 0.45 | Why? |
| Pulmonary Medicine | 1 | 2018 | 706 | 0.44 | Why? |
| Nasopharynx | 2 | 2021 | 10224 | 0.29 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2017 | 2984 | 0.25 | Why? |
| Tuberculosis | 1 | 2018 | 2895 | 0.24 | Why? |
| Lung Neoplasms | 1 | 2018 | 3228 | 0.22 | Why? |
| Time-to-Treatment | 1 | 2018 | 5883 | 0.22 | Why? |
| Intermediate Care Facilities | 1 | 2020 | 59 | 0.21 | Why? |
| Predictive Value of Tests | 3 | 2020 | 9537 | 0.20 | Why? |
| Thrombophlebitis | 1 | 2020 | 94 | 0.20 | Why? |
| Raynaud Disease | 1 | 2020 | 86 | 0.20 | Why? |
| Ulcer | 1 | 2020 | 128 | 0.19 | Why? |
| Tracheoesophageal Fistula | 1 | 2018 | 32 | 0.18 | Why? |
| Biopsy, Needle | 1 | 2018 | 303 | 0.17 | Why? |
| Esophagoscopy | 1 | 2018 | 95 | 0.17 | Why? |
| Tomography, X-Ray Computed | 2 | 2021 | 25144 | 0.16 | Why? |
| Tumor Burden | 1 | 2018 | 369 | 0.16 | Why? |
| Pulmonary Emphysema | 1 | 2018 | 122 | 0.16 | Why? |
| Lung | 3 | 2021 | 31049 | 0.16 | Why? |
| Omalizumab | 1 | 2019 | 158 | 0.16 | Why? |
| Airway Obstruction | 1 | 2019 | 182 | 0.16 | Why? |
| Diabetes Mellitus | 1 | 2018 | 8207 | 0.16 | Why? |
| Gastroesophageal Reflux | 1 | 2017 | 124 | 0.15 | Why? |
| Blood Cell Count | 1 | 2021 | 1101 | 0.15 | Why? |
| Italy | 10 | 2021 | 38444 | 0.14 | Why? |
| Respiration Disorders | 1 | 2021 | 526 | 0.14 | Why? |
| Emergency Service, Hospital | 4 | 2020 | 14232 | 0.14 | Why? |
| Administration, Inhalation | 2 | 2018 | 1647 | 0.14 | Why? |
| Reproducibility of Results | 3 | 2021 | 11304 | 0.14 | Why? |
| Cholecalciferol | 1 | 2017 | 246 | 0.14 | Why? |
| Prevalence | 4 | 2021 | 25773 | 0.13 | Why? |
| Scleroderma, Systemic | 1 | 2020 | 583 | 0.13 | Why? |
| Adrenal Cortex Hormones | 3 | 2020 | 6537 | 0.13 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.13 | Why? |
| Prognosis | 4 | 2021 | 32490 | 0.13 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.12 | Why? |
| Influenza, Human | 1 | 2017 | 10779 | 0.12 | Why? |
| Retrospective Studies | 10 | 2021 | 105322 | 0.12 | Why? |
| Platelet Aggregation Inhibitors | 2 | 2020 | 1671 | 0.11 | Why? |
| Middle Aged | 16 | 2022 | 270681 | 0.11 | Why? |
| Aged | 12 | 2021 | 215776 | 0.10 | Why? |
| Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 3832 | 0.10 | Why? |
| Humans | 27 | 2022 | 930598 | 0.10 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.10 | Why? |
| Hemodynamics | 1 | 2018 | 1562 | 0.10 | Why? |
| Anticoagulants | 3 | 2020 | 9563 | 0.10 | Why? |
| Hemorrhage | 2 | 2020 | 3013 | 0.10 | Why? |
| Lung Diseases, Interstitial | 1 | 2020 | 1476 | 0.10 | Why? |
| Image Processing, Computer-Assisted | 1 | 2018 | 1383 | 0.10 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.09 | Why? |
| Male | 14 | 2022 | 367725 | 0.09 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.08 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.08 | Why? |
| Lung Transplantation | 1 | 2018 | 1554 | 0.08 | Why? |
| Respiratory Rate | 2 | 2020 | 691 | 0.08 | Why? |
| Female | 14 | 2021 | 380317 | 0.07 | Why? |
| Dietary Supplements | 1 | 2017 | 2251 | 0.07 | Why? |
| Immunocompromised Host | 1 | 2021 | 5150 | 0.07 | Why? |
| Stress Disorders, Post-Traumatic | 1 | 2021 | 2963 | 0.07 | Why? |
| Lung Diseases | 1 | 2018 | 2361 | 0.07 | Why? |
| Triage | 2 | 2020 | 7151 | 0.07 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.07 | Why? |
| Vitamin D Deficiency | 1 | 2017 | 1782 | 0.07 | Why? |
| Occupational Exposure | 1 | 2022 | 4742 | 0.06 | Why? |
| Liver Diseases | 1 | 2018 | 2698 | 0.06 | Why? |
| Vitamin D | 1 | 2017 | 2904 | 0.06 | Why? |
| Aerosols | 1 | 2018 | 5393 | 0.06 | Why? |
| Societies, Medical | 1 | 2018 | 6907 | 0.06 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.06 | Why? |
| Time Factors | 3 | 2021 | 31397 | 0.05 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.05 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.05 | Why? |
| Pressure | 1 | 2020 | 289 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| Albuterol | 1 | 2019 | 105 | 0.04 | Why? |
| Airway Remodeling | 1 | 2019 | 111 | 0.04 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Clinical Deterioration | 1 | 2020 | 473 | 0.04 | Why? |
| Forced Expiratory Volume | 1 | 2019 | 632 | 0.04 | Why? |
| Oxygen Consumption | 1 | 2020 | 711 | 0.04 | Why? |
| Seroepidemiologic Studies | 2 | 2022 | 10017 | 0.04 | Why? |
| Oximetry | 1 | 2020 | 658 | 0.04 | Why? |
| Patient Discharge | 2 | 2021 | 5696 | 0.03 | Why? |
| Remission Induction | 1 | 2018 | 950 | 0.03 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2021 | 1755 | 0.03 | Why? |
| Adult | 6 | 2021 | 244371 | 0.03 | Why? |
| Eosinophils | 1 | 2019 | 848 | 0.03 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| Nitric Oxide | 1 | 2019 | 769 | 0.03 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.03 | Why? |
| Disseminated Intravascular Coagulation | 1 | 2020 | 994 | 0.03 | Why? |
| Telephone | 1 | 2020 | 1705 | 0.03 | Why? |
| Patient Readmission | 1 | 2020 | 1543 | 0.03 | Why? |
| Multivariate Analysis | 1 | 2021 | 5440 | 0.03 | Why? |
| Interdisciplinary Communication | 1 | 2017 | 1425 | 0.02 | Why? |
| Cross-Sectional Studies | 3 | 2022 | 53120 | 0.02 | Why? |
| Thrombophilia | 1 | 2020 | 1935 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2020 | 6543 | 0.02 | Why? |
| Equipment Design | 1 | 2018 | 3095 | 0.02 | Why? |
| Incidence | 2 | 2020 | 25622 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| Logistic Models | 1 | 2020 | 9089 | 0.02 | Why? |
| Antirheumatic Agents | 1 | 2020 | 3023 | 0.02 | Why? |
| Ultrasonography | 1 | 2020 | 4409 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.02 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Pulmonary Embolism | 1 | 2020 | 4775 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Health Personnel | 2 | 2022 | 29646 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.01 | Why? |
| Antibodies, Viral | 2 | 2022 | 51949 | 0.01 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.01 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.01 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.01 | Why? |
| Prospective Studies | 1 | 2020 | 43301 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2022 | 29620 | 0.01 | Why? |
| Treatment Outcome | 1 | 2017 | 51732 | 0.01 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.01 | Why? |
| Young Adult | 1 | 2017 | 93724 | 0.00 | Why? |
Patrucco's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(144)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(213)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_